Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Pediatric ADHD News

FDA Approves First Liquid, Non-Stimulant for Pediatric ADHD
News
FDA Approves First Liquid, Non-Stimulant for Pediatric ADHD
06/11/2024
Evi Arthur
The FDA approved Tris Pharma, Inc.’s ONYDA™ XR (clonidine hydrochloride), a once-daily extended-release oral suspension medication, for the treatment of ADHD in patients 6 years and older.
The FDA approved Tris Pharma, Inc.’s ONYDA™ XR (clonidine hydrochloride), a once-daily extended-release oral suspension medication, for the treatment of ADHD in patients 6 years and older.
The FDA approved Tris Pharma,...
06/11/2024
Psych Congress Network
pediatric adhd
News
Several Treatments Effective in Youth With ADHD, but Evidence Strongest for Medication
05/31/2024
Jolynn Tumolo
While treatments that improve attention-deficit/hyperactivity disorder (ADHD) in children and adolescents are diverse and growing, medications have the strongest evidence base for improved outcomes.
While treatments that improve attention-deficit/hyperactivity disorder (ADHD) in children and adolescents are diverse and growing, medications have the strongest evidence base for improved outcomes.
While treatments that improve...
05/31/2024
Psych Congress Network
A young Black boy sits on the floor of a living room holding a video game controller and concentrated on his game
News
Virtual Gaming May Enhance Working Memory for Youth With ADHD
05/17/2024
Brionna Mendoza
A literature review presented via poster at the 2024 American Psychiatric Association Annual Meeting in New York City suggests that video games may not be all-harm in effect for youth with ADHD.
A literature review presented via poster at the 2024 American Psychiatric Association Annual Meeting in New York City suggests that video games may not be all-harm in effect for youth with ADHD.
A literature review presented...
05/17/2024
Psych Congress Network

Advertisement

A young child wears goofy sunglasses and smiles
News
Acetaminophen Use During Pregnancy Not Associated With ADHD, Other Neurodevelopmental Disorders
04/15/2024
Brionna Mendoza
Acetaminophen use during pregnancy does not increase children’s risk of neurodevelopmental disorders, including attention-deficit/hyperactivity disorder (ADHD), autism, and intellectual disability.
Acetaminophen use during pregnancy does not increase children’s risk of neurodevelopmental disorders, including attention-deficit/hyperactivity disorder (ADHD), autism, and intellectual disability.
Acetaminophen use during...
04/15/2024
Psych Congress Network
A Black infant with bantu knots holds an alphabet letter block
News
Genetic Links Between Vocabulary and Later-Life ADHD Shift Over Infancy and Toddlerhood
04/01/2024
Jolynn Tumolo
A larger span of spoken words was genetically linked with an increased risk of attention-deficit/hyperactivity disorder (ADHD) and more ADHD symptoms in infants, but by toddlerhood the genetic relationship was reversed.
A larger span of spoken words was genetically linked with an increased risk of attention-deficit/hyperactivity disorder (ADHD) and more ADHD symptoms in infants, but by toddlerhood the genetic relationship was reversed.
A larger span of spoken words...
04/01/2024
Psych Congress Network
A child lies in bed with a thermometer in mouth and cool cloth on forehead
News
Fever Episodes Before Age 4 May Raise Risk of Childhood ADHD
03/01/2024
Brionna Mendoza
Episodes of fever experienced during the first 4 years of life are associated with a higher rate of attention-deficit/hyperactivity disorder (ADHD) diagnosis during childhood and demonstrates a dose-response relationship.
Episodes of fever experienced during the first 4 years of life are associated with a higher rate of attention-deficit/hyperactivity disorder (ADHD) diagnosis during childhood and demonstrates a dose-response relationship.
Episodes of fever experienced...
03/01/2024
Psych Congress Network

Advertisement

a boy with adhd
News
Childhood Lead Exposure Found to Be Positively Associated With ADHD Diagnosis
02/15/2024
Brionna Mendoza
Exposure to lead during childhood, but not prenatal exposure, may increase the chances of subsequent attention-deficit/hyperactivity disorder (ADHD) symptoms and diagnosis.
Exposure to lead during childhood, but not prenatal exposure, may increase the chances of subsequent attention-deficit/hyperactivity disorder (ADHD) symptoms and diagnosis.
Exposure to lead during...
02/15/2024
Psych Congress Network
a young boy looks sad
News
Children With ADHD and Psych Comorbidities at Higher Risk for Schizophrenia
02/09/2024
Jolynn Tumolo
Children and adolescents with attention-deficit/hyperactivity disorder (ADHD) and psychiatric comorbidities had a 2-fold higher risk of a subsequent schizophrenia diagnosis compared with those with ADHD and no comorbidities.
Children and adolescents with attention-deficit/hyperactivity disorder (ADHD) and psychiatric comorbidities had a 2-fold higher risk of a subsequent schizophrenia diagnosis compared with those with ADHD and no comorbidities.
Children and adolescents with...
02/09/2024
Psych Congress Network
a doctor holds a generic orange pill bottle
News
Zenzedi CII 30 mg Tablets Recalled Over Mislabeling Concerns
01/29/2024
Meagan Thistle
zurity Pharmaceuticals, Inc. has issued a voluntary recall of 1 lot of Zenzedi CII 30 mg tablets after a Nebraska pharmacist discovered carbinoxamine maleate, an antihistamine, in a bottle labeled as Zenzedi 30 mg.
zurity Pharmaceuticals, Inc. has issued a voluntary recall of 1 lot of Zenzedi CII 30 mg tablets after a Nebraska pharmacist discovered carbinoxamine maleate, an antihistamine, in a bottle labeled as Zenzedi 30 mg.
zurity Pharmaceuticals, Inc. has...
01/29/2024
Neurology

Advertisement

brain network
News
Comorbid Tics, Stereotypies Common in Typically Developing Patients, Review Finds
01/09/2024
Jolynn Tumolo
Tics and stereotypies often co-occur in otherwise typically developing pediatric patients, according to a systematic literature review.
Tics and stereotypies often co-occur in otherwise typically developing pediatric patients, according to a systematic literature review.
Tics and stereotypies often...
01/09/2024
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use